Skip to Main Content

Pfizer said Wednesday afternoon that a closely watched gene therapy for Duchenne muscular dystrophy failed to slow the disease’s progression in a Phase 3 trial.

This is now the second large, randomized, placebo-controlled trial of a Duchenne gene therapy to fail to reach its primary endpoint, a composite scale of muscle function designed specifically for the rare disease. A similar study of a Sarepta gene therapy failed last year, although the company pointed to secondary measures as evidence that its treatment was still slowing the fatal, muscle-wasting condition.

advertisement

Pfizer said that in its study, which enrolled 99 boys between ages 4 and 7 and followed them for a year, its gene therapy did not show any difference on those key secondary endpoints.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.